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ABSTRACT
Pneumonia is an infection of the lungs, where the alveoli in the affected area are filled with pus
and fluid. Although ventilated patients are at risk, not all ventilated patients develop pneumonia.
This suggests that the sputum environment may possess antimicrobial activities. Despite the
generally acknowledged importance of antimicrobial activity in protecting the human lung
against infections, this has not been systematically assessed to date. Therefore, the objective of
the present study was to measure antimicrobial activity in broncho-alveolar aspirate (‘sputum”)
samples from patients in an intensive care unit (ICU) and to correlate the detected antimicrobial
activity with antibiotic levels, the sputum microbiome, and the respective patients’ characteristics.
To this end, clinical metadata and sputum were collected from 53 mechanically ventilated ICU
patients. The antimicrobial activity of sputum samples was tested against Streptococcus pneumo-
niae, Staphylococcus aureus and Streptococcus anginosus. Here we show that sputa collected from
different patients presented a high degree of variation in antimicrobial activity, which can be
partially attributed to antibiotic therapy. The sputum microbiome, although potentially capable of
producing antimicrobial agents, seemed to contribute in a minor way, if any, to the antimicrobial
activity of sputum. Remarkably, despite its potentially protective effect, the level of antimicrobial
activity in the investigated sputa correlated inversely with patient outcome, most likely because
disease severity outweighed the beneficial antimicrobial activities.
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In a healthy individual, the bacterial community of the
lower respiratory tract mostly resembles that of the oral
cavity [1,2]. However, bacteria are significantly less
abundant in the lungs. This is related to effective clear-
ing by a variety of mechanisms, including ciliated
epithelium generating an “outward” flow of mucus,
coughing [3,4] and immune defenses [5]. Nonetheless,
disturbances in this well-balanced system may occur
and ultimately lead to infectious diseases, pneumonia
in particular [6].
Pneumonia is an infection of the lungs caused by
bacteria, fungi or viruses, as stated by the World Health
Organization (http://www.who.int/news-room/fact-
sheets/detail/pneumonia), the Centers for Disease
Control and Prevention (https://www.cdc.gov/pneumo
nia/) and others [7,8]. Literature differentiates between
Community-Acquired Pneumonia (CAP) and Hospital-
Associated Pneumonia (HAP). By definition, the onset of
CAP takes place outside the hospital. However, since CAP
may manifest itself shortly after the actual admission of
patients in the hospital, cases of pneumonia occurring
within 48 hours of hospital admission are usually defined
as CAP. Accordingly, HAP is usually defined as
a pneumonia occurring 48 hours ormore after admission.
Furthermore, the causative agents of CAP are oftentimes
different and less resistant to antibiotics than those that
cause HAP [9–11]. However, a precise distinction
between CAP and HAP can be difficult. A particular
risk factor is mechanical ventilation that may lead to so-
called Ventilator-Associated Pneumonia (VAP). VAP
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usually arises 48 hours after endotracheal intubation
[9,12], with a subdivision into early onset (within 4 days
of hospital admission) and late onset VAP (after 4 days of
hospital admission) [12]. Around 9–31% of the mechani-
cally ventilated patients develop VAP depending on the
clinical setting [13,14]. Main causative bacteria in VAP
are Staphylococcus aureus, Pseudomonas aeruginosa,
Klebsiella pneumoniae, Escherichia coli, Enterobacter spe-
cies and (non-typeable; NTHi) Haemophilus influenzae.
Streptococcus pneumoniae can also cause infection in
VAP, but this is less common [15–19].
The alveolar sacs of the lung are filled with air in
a healthy individual, but in patients with pneumonia
the alveoli in the affected area are filled with pus and
fluid (“sputum”) (World Health Organization, http://
www.who.int/news-room/fact-sheets/detail/pneumo
nia). Sputum is an excessive amount of mucus with
a composition that differs per individual and over
time [20–23]. A main component is the glycoprotein
mucin, but also DNA, filamentous actin, proteoglycans,
biofilms, bacteria, antimicrobials and antibiotics may
be present [20,24–27]. The accumulation of sputum in
the lungs is a potential risk factor for pneumonia as it
may represent an ecological niche for microorganisms.
However, the fact that not all ventilated patients
develop pneumonia suggests that the sputum environ-
ment may possess antimicrobial activities, which is
a possibility that has not been systematically investi-
gated to date. Accordingly, the objective of the present
explorative study was to measure antimicrobial activity
in broncho-alveolar aspirate samples (sputa) from
patients in an intensive care unit (ICU) of the
University Medical Center Groningen (UMCG), and
to correlate the detected antimicrobial activity with
antibiotic levels, the sputum microbiome and the
respective patients’ characteristics.
Material and methods
Patients and sputum collection
From February to August 2015, nurses collected spu-
tum from mechanically ventilated patients (Figure 1)
admitted to the department of Critical Care of the
UMCG. Patient exclusion criteria were suspicion or
diagnosis of tuberculosis, fungal or viral infections,
immunodeficiency, administration of cytostatic agents,
or positive end expiratory pressure >10 cm H20.
Diagnostic culturing of sputa was performed within
24 h after sampling according to the standard diagnos-
tic routine at the UMCG. Sputum samples used for
other analyses were initially stored at 4°C, and as
soon as possible aliquoted and frozen at −20°C.
Where possible, multiple samples from the same
patient were collected and numbered chronologically.
Initially, 58 patients were enrolled in this study.
However, in the course of the study, it turned out
that 1 patient was enrolled twice and 4 patients were
excluded, either because of treatment with cytostatic
agents, loss of the sputum sample, or inconsistency of
recorded patient data. Ethical approval for this study
was obtained from the Medical Ethical Committee of
the UMCG (research project number 2014.309), which
decided that informed consent was not necessary since
all patients admitted to the UMCG are informed that
their data and (diagnostic) waste materials can be used
for scientific research. All patient data and samples
were collected with adherence to the Helsinki
Guidelines and processed anonymously.
Collection of sputum-resident microorganisms
Before storing sputum samples at −20°C, they were
streaked on 5% sheep blood agar (BA), chocolate agar
(CHOC), and MacConkey agar no.3 (MCC3) plates
(Mediaproducts BV, the Netherlands). Plates were
incubated at 37°C with (BA, CHOC) or without
(MCC3) 5% CO2 according to standard diagnostic rou-
tine. Single colonies were then picked and, after sub-
culture, the respective microorganisms (bacteria and
yeasts) were suspended in tryptic soy broth (TSB,
Oxoid) with 11% glycerol and stored at −80°C.
Bacterial strains and growth conditions
S. pneumoniae TIGR4 (serotype 4) [28] and Streptococcus
anginosus 009–1 (clinical isolate from sputum sample
009–1, this study) were grown as standing cultures
in M17 broth (Oxoid) with 0.5% glucose (GM17) at 37°C.
S. aureus HG001 [29] was grown in TSB at 37°C under
shaking conditions (250 rpm).
Sputum spotting assay to measure antimicrobial
activity
Large BA plates were prepared by pouring blood agar base
no.2 (Oxoid) supplemented with sheep blood (Thermo
Scientific; 5% final concentration) into Nunc™ Square
BioAssay Dishes (245x245x25 mm, Thermo Scientific).
The bacterial indicator strains S. pneumoniae TIGR4,
S. anginosus 009–1 and S. aureusHG001 were grown over-
night in GM17 or TSB, diluted in freshmedium and grown
till an optical density at 600 nm (OD600) of ~0.25
(S. pneumoniae TIGR4 and S. aureus HG001) or ~0.14
(S. anginosus 009–1). 450 µl of culture was streaked evenly
on a BAplate, using a cotton swab thatwas humidifiedwith
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phosphate-buffered saline (PBS). Sputum samples were
quickly thawed in a 37°C water bath, vortexed and aliquots
of ~15 µl were spotted on BA plates with the respective
indicator bacteria. These plates were then incubated over-
night at 37°C and 5% CO2. Images were recorded with a G:
Box (Syngene, Leusden, the Netherlands), and antimicro-
bial activity of sputum samples was assayed by measuring
the size of growth inhibition zones with ImageJ [30].
Cefotaxime quantification in sputum samples and
Etest
Mechanically ventilated patients at the department of
Critical Care of the UMCG are subject to selective
decontamination of the digestive tract (SDD) if the dura-
tion of mechanical ventilation is expected to exceed 48
h and/or if the expected duration of the admission
exceeds 78 h [31]. SDD is intended to prevent secondary
colonization with Gram-negative bacteria, S. aureus, and
yeasts through: (i) the application of non-absorbable anti-
microbial agents (i.e. tobramycin, colistin, and amphoter-
icin B) in the oropharynx and gastrointestinal tract, and
(ii) preemptive treatment of possible infections with com-
mensal respiratory tract bacteria through systemic admin-
istration of cephalosporins (especially cefotaxime) during
the patient’s first four days in the ICU [31]. To determine
cefotaxime concentrations in sputum, flash-frozen spu-
tum aliquots of ~100 µl were cryofractured twice with
Figure 1. Schematic representation of sputum collection and sample processing, storage and analysis. (a) Image of sputum collection
from a mechanically ventilated patient. A mechanical ventilation machine [1] supplies the intubated patient [2] with warm humidified air.
Sputum is collected by attaching an external collection tube [3] to a tube (4a-b) that is connected to the intubation tube. The tube on the
other end [5] of the collection tube is connected to a vacuumpump. The vacuum can be applied to this closed system by pressing a button
(4a), and the tube for sputum collection (4b) is then inserted into the patient’s lungs. Some saline [6] can simultaneously be introduced
into the lung to ease the sputum extraction. (b) Schematic representation of the workflow following sputum collection. The collected
sputum is (i) processed for storage and further analyses (i.e. spotting on indicator bacteria, determination of residual antibiotics and 16S
rRNA analysis), and (ii) plated for collection of microorganisms present in the sputum and subsequent assessment of the production of
antimicrobial agents (i.e bacteriocins) by spotting on plates with indicator bacteria.
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a cryoPREP CP02 (Covaris) at maximum power using
tissueTUBE TT1 Extra Think sample bags (Covaris).
Sample extraction was subsequently performed by adding
1000 µl ice-cold 60% methanol and centrifugation
(17,096 x g, 3 min, 4°C). Extracts were stored at −20°C
until further analysis. To process the samples for high-
performance liquid chromatography (HPLC) – mass
spectrometry (MS) analyses, 100 µl deionized water was
added to 200 µl of extract, followed by the addition of
25 µl 1% citric acid and 25 µl of the internal standard
4-hydroxychalcone (1 µg/ml; Sigma). Methanol was
removed by vacuum evaporation (Scanvac) at 2000 rpm,
for 15 min at room temperature. HPLC-MS/MS analyses
were performed with an Agilent 1100 series HPLC system
(Agilent Technologies, Waldbronn, Germany) coupled to
an API4000 mass spectrometer (Sciex, Darmstadt,
Germany) using an Atlantis® Silica HILIC column (3 µm
2.1 × 100 mm; Waters Corporation, Milford, MA) with
isocratic elution (50% acetonitrile, 50% ammonium acet-
ate (5 mM, pH 3.8)) at a flow rate of 200 µl/min. The
lower limit quantification for cefotaxime in sputum
extracts was 0.8 ng/ml. Because of the viscosity of sputum,
the weight of each sample was measured and the cefotax-
ime concentration was calculated based on the assump-
tion that sputum has an average density of one.
The minimal inhibitory concentration (MIC) of
S. pneumoniae TIGR4, S. anginosus 009–1 and
S. aureus HG001 for cefotaxime was determined
with M.I.C.Evaluator strips (MA0111D, Oxoid) on
Mueller Hinton II agar with 5% sheep blood (for strep-
tococci) or regular Mueller Hinton agar (EUCAST; for
S. aureus) (Mediaproducts BV, the Netherlands).
Strain spotting assay to detect antimicrobial
activity produced by sputum isolates
Bacteria and yeasts isolated from sputum samples with
antimicrobial activity were grown overnight as standing
cultures in Brain Heart Infusion (BHI) broth (Oxoid) or
TSB at 37°C and 5% CO2. The overnight cultures were
vortexed and aliquots of 2 µl were spotted on BA plates
with indicator bacteria. In those cases where sputum
isolates did not grow in BHI or TSB, the respective isolates
were grown overnight on BA plates. Subsequently, colo-
nies were suspended in PBS and aliquots of 2 µl were used
for spotting on BA plates with indicator bacteria. Plates
with indicator bacteria and spotted sputum isolates were
incubated and analyzed as described above.
Bacterial identification by MALDI-TOF MS
The S. anginosus sputum isolate from sample 009–1 was
identified by MALDI-TOF MS as described previously
[32]. In brief, the isolate was cultured on blood agar at
37°C and 5%CO2. Individual colonies were transferred in
duplicate onto a stainless-steel MALDI target using
a toothpick. Upon drying at room temperature, 1 μl of
a matrix solution, composed of α-cyano-4-hydroxycin-
namic acid in 50% acetonitrile/2.5% trifluoro-acetic acid
(HCCA), was added to the first spot. For so-called on-
target extraction, the second spot was overlaid with 1 μl of
70% formic acid prior to the addition of 1 μl HCCA
matrix. The samples were then analyzed with a Bruker
microflex MALDI-TOFMS system using the Biotyper 3.0
software (Bruker Daltonik, Bremen, Germany).
16S rRNA sequencing
Sputum aliquots of ~100 µl were used for total DNA
extraction with the Zymo Quick DNA kit (Zymo
Research, CA, USA). A liquid culture of S. pneumoniae
TIGR4 served as a positive control, and the kit ingredients
were used as a negative control. Polymerase chain reac-
tion (PCR) amplification, PCR cleanup, MiSeq library
preparation and sequencing with an Illumina MiSeq
System (Illumina Inc. San Diego, USA) were performed
as described by Heida et al. [33]. Briefly, sputum DNA
was used to amplify the V3-V4 region of the 16S rRNA
gene by PCR using modified 341F and 806R primers with
a 6-nucleotide index sequence on the 806R primer, as
published by Bartram et al. [34]. The resulting FASTQ
files with Illumina paired-end reads were processed with
PANDAseq, the taxonomy at phylum, family and genus
levels was defined with the open source software package
QIIME, and ARB was subsequently used to define isolates
at the species level [33,35,36]. Samples with less than 1000
reads in total were excluded from further analysis.
Heatmaps were generated by using R package version
3.3.3 and edited with Adobe Illustrator CC 2017.
The BAGEL4 webserver was used to determine the
possible presence of genes encoding bacteriocins or
ribosomally synthesized and post-translationally mod-
ified peptides (RiPPs) in genomes of interest [37].
These analyses were based on up to three randomly
selected publicly available genome sequences of species
identified by 16S rRNA sequencing.
Statistical analyses
Statistical analyses, including Principal Component
Analyses (PCA), t-tests, Mann-Whitney U tests,
Pearson’s chi-squared tests and a Spearman test were
performed with the Statistical Package for Social
Science version 25 (SPSS, IBM). A p-value ≤ 0.05 was
considered statistically significant.
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Results
Cohort of mechanically ventilated ICU patients
To collect sputum samples, a study cohort of 53
patients was recruited from 58 eligible mechanically
ventilated patients admitted to the Neuro ICU of the
department of Critical Care of the UMCG. The baseline
and clinical characteristics variables of the patients
included in this study are summarized in Table 1. An
overview of the antibiotics administered to the patients
during ICU admission is presented in Supplemental
Table S1. Of note, no information is available on anti-
biotics prescribed prior to admission to the ICU.
Antimicrobial activity in patient sputa
Sputum samples were collected by aspiration during rou-
tine ICU patient care as represented in Figure 1.
Subsequently, the collected sputa were tested for antimi-
crobial activity in a spotting assay, where aliquots were
transferred to a plate with the indicator bacteria
S. pneumoniae TIGR4, S. anginosus 009–1 or S. aureus
HG001. Here the S. anginosus isolate 009–1 served as
a sputum-resident control bacterium. Upon overnight
incubation at 37°C, antimicrobial activity in particular
sputum samples was evidenced by zones of growth inhi-
bition of the indicator bacteria. The results are shown in
Figure 2. Overall, large differences in the extent of growth
inhibition were observed for different sputum samples
from different patients (Table S2 and S3). Furthermore,
the highest degree of “sputum sensitivity” was observed
for S. pneumoniae, whereas S. aureus displayed the lowest
sensitivity to the applied sputa. In extreme cases, major
growth inhibition was observed for S. pneumoniae, while
S. aureus was not inhibited at all (Figure 2; A2-3, B7, C6,
D7-8, E2, E5, I3-5, K6, L3-4, O2, P1 and P3). Conversely,
three sputa inhibited the growth of S. aureus without
affecting S. pneumoniae (Figure 2; B3, D2, P6). The sensi-
tivity of S. anginosus to the different sputa was largely
comparable to that of S. pneumoniae, albeit that the
analysis also showed several clear differences (Figure 2;
A3, B6-7, C5-6, D7, E2, F1, I3-4, K6, L4, M2-3, and P1-3).
Of note, 25 sputa displayed no detectable antimicrobial
activity against the three indicator bacteria (Figure 2; A4-
8, B1-2, B4-5, E6-7, F2-3, F6, I2, K2, K4-5, N2-3, O5, O8,
P4, and P7-8). Together, these observations show that
many of the sputa displayed significant antimicrobial
activity, which may have originated from antimicrobial
therapy of the respective patients (Supplemental Table
S1), the “sputum microbiota”, or the patient’s innate
immune defenses.
Detection of cefotaxime in isolated sputa
Forty-four of the 53 included patients had received anti-
biotics intravenously, either to treat or prevent an infection.
In particular, 33 patients were treated with cefotaxime; 25
of these patients received this antibiotic as monotherapy,
whereas 3 patients were treated with cefotaxime in combi-
nation with ciprofloxacin and 5 patients with cefotaxime
and another antibiotic. Eleven patients were treated with
(combinations of) other antibiotics (Supplemental Table
S1, Figure 3(a)). Since cefotaxime wasmost frequently used
as part of the SDD-infection-prevention regimen, we
examined the presence of this antibiotic in sputum by
HPLC-MS/MS. Of note, cefotaxime was only measured
in samples from those patients who received cefotaxime
as a monotherapy, provided that sufficient sputum was
available for this analysis. The results presented in Table
S4 show that the measured cefotaxime concentrations in
sputum samples ranged from zero to 0.340 µg/ml. In fifteen
samples no cefotaxime was detectable. Remarkably, the
measured cefotaxime concentration in sputa cannot be
directly related to the pneumococcal growth inhibition
Table 1. Baseline characteristics and clinical variables of
included ICU patients (n = 53).




Age median (years) 58.0 [41.5–71.0] {19.0–85.0}
Hospital LOS (days) 18.6 [9.8–32.2] {0.8–75.5}








Hospital Transfer 37 (69.8)
Deceased 14 (26.4)
Nursing home 2 (3.8)
Mech. Vent. (hours) 134.0 [84.0–301.0] {13.0–1809.0}
COPD 2 (3.8)
Pneumonia 18 (34.0)
SAPS II 49.0 [37.0–57.5] {19.0–72.0}
APACHE IVa 78.0 [58.5–88.0] {29.0–126.0}
I.V. antibiotics 44 (83.0)
SDD topical antibiotics 42 (79.2)
Corticosteroids 16 (30.2)
Leukocytes
Sample§b 12.3 [9.3–15.4] {4.4–30.0}
Lowest§§ 8.0 [6.0–9.6] {2.1–17.7}
Highest§§§ 18.3 [15.4–23.7] {8.1–53.2}
CRP
Sample§b 68.0 [37.0–131.5] {1.8–319.0}
Lowest§§ 5.5 [1.4–27.5] {0.3–264.0}
Highest§§§ 133.0 [76.0–210.0] {16.0–465.0}
IQR, interquartile range; LOS, length of stay; ICU, intensive care unit; Mech.
Vent., mechanical ventilation; COPD, Chronic Obstructive Pulmonary
Disease; SAPS, Simplified Acute Physiology Score; APACHE, Acute
Physiology and Chronic Health Evaluation; I.V., intravenous; SDD, selective
decontamination of the digestive tract; CRP, C-reactive protein.
§Leukocytes/CRP measured in blood at the time of first sputum sample
collection, §§Lowest leukocytes/CRP measured in blood during ICU admis-
sion, §§§Highest leukocytes/CRP measured in blood during ICU admission.
aAvailable for 50 patients; bavailable for 49 patients.
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zones observed upon sputum spotting, as shown by the
scatter plot in Figure 3(b). A Spearman test confirmed this
observation with a non-significant (p = 0.767) correlation
coefficient of 0.052 (n = 35). Of note, samples without
a quantifiable cefotaxime concentration and pneumococcal
growth inhibition zone were excluded from the Spearman
test (n = 11), to avoid a spurious overestimation of the
correlation. Moreover, in particular sputum samples in
which cefotaxime was detectable by HPLC-MS/MS, no
growth inhibition of S. pneumoniae was observed (Table
S4; Figure 2). This implies that at least part of the sputum-
associated cefotaxime may be present in a state in which it
cannot exert its antibiotic activity.
Potential antimicrobial activity produced by
sputum microbiota
Remarkably, in some cases the measured concentration of
cefotaxime was below the MIC value of S. pneumoniae
TIGR4 (0.015 µg/ml), while the respective sputa still
inhibited growth (Table S4; Figures 2 and 3(b)).
Moreover, four samples from two patients who did not
receive antibiotics intravenously showed significant pneu-
mococcal inhibition (Figure 2; I3-4 and P2-3). This was
suggestive of antimicrobial activity produced by the spu-
tum microbiota or the patient. To test the influence of the
“sputum microbiome”, microbes isolated from sputa with
antimicrobial activity were spotted onto BA plates with the
indicator bacteria S. pneumoniae TIGR4, S. anginosus
009–1 or S. aureus HG001. Of note, only isolates from
patients who had not been intravenously treated with anti-
biotics were selected for this analysis to avoid false-positive
results. Upon overnight incubation at 37°C, plates were
examined for possible growth inhibition. As shown in
Figure 4, some of the spotted isolates (Table S5) exerted
marginal growth inhibitory effects on S. pneumoniae, while
zero growth inhibition of S. anginosus and S. aureus was
observed. On the other hand, S. aureus HG001
exerted antimicrobial activity on several spotted sputum
isolates and allowed only significant growth of four spotted
Figure 2. Detection of antimicrobial activity in sputa. 125 sputum samples from 56 different patients were spotted on blood agar plates
with confluent lawns of the indicator bacteria S. pneumoniae TIGR4, S. anginosus 009–1 and S. aureus HG001. The antimicrobial activity in
particular sputa is depicted by cleared zones of growth inhibition. Of note, this assay was performed before completion of the analysis of
patient data. Since three patients were subsequently excluded from the study (see materials and methods), the results for the six
respective sputum samples (G4, H5-6, K7-8 and L1) are covered in the image. One sputum sample (F4) could not be applied to the plates,
because the sputum sample was too viscous for quantitative spotting; for two other samples the results are covered (E8, F7), because
insufficient amounts of sputum were available to test them against all three species of indicator bacteria. The topography of sputum
samples spotted onto lawns of the indicator bacteria is described in Supplemental Table S2.
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isolates (Figure 4; B1, B4, B6, D2). This is consistent with
the presence of an operon for production of the lantibiotic
Gallidermin in the genome of S. aureus HG001 as identi-
fied with the BAGEL4 algorithm.
Figure 3. Pneumococcal growth inhibition related to administered antibiotics or actual cefotaxime concentrations in collected sputum
samples. (a) Scatter plot of pneumococcal growth inhibition versus the intravenously administered antibiotics as detailed in Supplemental
Table S1. The median inhibition is shown behind the (combination of) antibiotics on the Y-axis. (b) Scatter plot of pneumococcal growth
inhibition versus the measured cefotaxime concentration in sputum. The red dashed line indicates the MIC of cefotaxime for S. pneumoniae
TIGR4. Note that several samples with cefotaxime concentrations above the MIC for S. pneumoniae TIGR4 show no growth inhibition, whereas
other samples with cefotaxime concentrations lower than the MIC for S. pneumoniae TIGR4 show strong pneumococcal growth inhibition.
Importantly, cefotaxime was only measured in samples from patients who received cefotaxime as monotherapy during ICU admission.
Figure 4. Antagonistic actions between bacterial sputum isolates and indicator bacteria. 14 microbial isolates from seven sputum
samples of three different patients were spotted on blood agar with confluent lawns of the indicator bacteria S. pneumoniae TIGR4,
S. anginosus 009–1 and S. aureus HG001. Note that none of the spotted isolates caused growth inhibition of the indicator bacteria,
whereas S. aureus HG001 did inhibit growth of some of the spotted isolates. The topography of bacterial samples spotted onto lawns
of the indicator bacteria is detailed in Supplemental Table S5.
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Identification of sputum microbiomes
To investigate whether the microbiomes of sputa with
or without antimicrobial activity isolated from particu-
lar patients differ, we analyzed the microbial population
in 33 sputa by sequencing the respective 16S rRNA
genes. Of note, the sample selection was based on two
criteria, namely: (i) sputa from a particular patient
displayed at least in one case antimicrobial activity
against S. pneumoniae, but this patient had not been
treated intravenously with antibiotics; and (ii) sputa
from patients with at least one sample being inhibitory
to both S. pneumoniae and S. aureus. Six out of the 33
samples were excluded after 16S rRNA sequencing,
because their total number of reads were found to be
less than the threshold of 1000 reads. In the remaining
27 samples 635 species were identified. The heatmap of
Figure 5 is based on the 30 bacterial species that
showed on average the highest relative abundance in
all samples. Overall, the sputum microbiome was found
to be highly heterogeneous with Streptococcus thermo-
philus, Staphylococcus epidermidis, and Streptococcus
mitis being the most frequently identified sputum-
resident bacteria. These bacteria were detected in 27,
26 and 25 sputum samples, respectively. Importantly,
16S rRNA sequencing identified S. anginosus in sputum
sample 009–1 with a low relative abundance, but the
detection of this species is consistent with its isolation
from the same sample as described above. In general,
bacterial species that were detected by routine diagnos-
tic culturing were also detected through 16S rRNA
sequencing (Table S6), while yeasts and fungi remained
undetected due to the specific primers used.
Altogether, the 16S rRNA analysis showed that sam-
ples from the same patient mostly cluster together
(Figure 5). Only the two samples from patient 009
and the two samples from patient 060 were separated,
suggesting that the sputum microbiome of these
Figure 5. Heatmap of microbial abundance in sputum. The heatmap was generated based on a hierarchical clustering solution
(Euclidean distance metric and average linkage) of the sputum microbiome samples (n = 27). Rows represent species identified by
16S rRNA sequencing, and columns represent individual sputum samples. The heatmap is sorted according to the dendogram
analyses, based on the relative abundance of particular species. The color key for relative abundance of the different species is
presented on the right of the heatmap. Positive and negative controls were performed, but the respective results are not presented
in the heatmap. The panels below the heatmap present the detected antimicrobial activity in each sputum sample (in mm; color-
coded in accordance with the key on the right), and selected patient characteristics relating to (antimicrobial) therapy in the ICU,
lung diseases and ICU survival (black indicates “yes”). Importantly, information in the latter panel is shown per sample. An additional
bar plot of the microbial abundance per sputum sample is shown in Supplemental Figure S1, and a heatmap of the microbial
abundance in sputum samples related to the respective antimicrobial activity against the indicator strain S. pneumoniae TIGR4 is
presented in Supplemental Figure S3.
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patients had changed in the period between the collec-
tion of the two samples (see also Figure S1 and Table
S7). Figure 5 also summarizes patient data on the
administration of antimicrobial therapy and corticos-
teroids, lung diseases and ICU survival, but these data
reveal no significant differences. Lastly, Figure 5 pre-
sents the anti-pneumococcal activity of the sputum
samples as inferred from the size of the inhibition
halos in Figure 2. The combined data show that there
is no correlation between the sputum microbiome and
antimicrobial activity against S. pneumoniae TIGR4.
This view is supported by PCA analysis at the species
level that revealed no differentiating clusters of inhibit-
ing or non-inhibiting samples (Figure S2). To assess
whether the species identified by 16S rRNA sequencing
have the potential to produce antimicrobial activities,
a BAGEL4 analysis was performed. This revealed the
presence of predicted bacteriocin genes in 13 out of the
27 identified species, where it should be noted that for 3
identified species no genome sequence is publicly avail-
able (Figure S3). Yet, this bioinformatic analysis did not
uncover possible correlations between the predicted
potential to produce bacteriocins and the actual anti-
microbial activities measured in the investigated sputa
(Figure S3). These findings imply that antimicrobial
activity in the investigated sputa is most likely due to
therapeutic interventions and host factors, whereas
there is little, if any, antimicrobial activity contributed
by the sputum microbiome.
Relationships between patient characteristics and
antimicrobial activity
Mann-Whitney U, t-tests and Chi square analyses were
performed to assess possible relationships between the
patient characteristics and the antimicrobial activity
against S. pneumoniae TIGR4 in either the first sputum
sample collected from the different patients, or the aver-
aged antimicrobial activities against S. pneumoniae
TIGR4 in all samples from particular patients (Table
S8). Two baseline characteristics, the SAPS II and
APACHE IV scores, were significantly higher among
patients with a first sputum sample with antimicrobial
activity (Table S8). Patients with antimicrobial activity in
their sputa on average also had significantly higher SAPS
II scores and within this group, significantly more
patients were treated intravenously with antibiotics
(Table S8). Further, both among patients with antimicro-
bial activity in the first collected sputum sample and
patients with antimicrobial activity in one or more
sputa, significantly more patients received antibiotics
intravenously for clinical reasons (Table S8, “other anti-
biotics”). Although the lowest measured CRP levels were
significantly higher among patients with antimicrobial
activity in the averaged samples (Table S8), there was no
overall difference in the CRP levels of patients with or
without antimicrobial activity in their sputa.
Patient characteristics that influence the patient’s
outcome
To investigate the possible influence of different patient
characteristics on patients’ outcome in the ICU, the
baseline characteristics of patients with or without
pneumonia, and patients who survived or passed away
in the ICU, were compared (Table 2). Patients with
pneumonia stayed longer in the ICU as compared to
patients without pneumonia, though overall the differ-
ence was not statistically significant. In addition,
patients with pneumonia were significantly longer
mechanically ventilated than patients who did not
develop pneumonia, and they had higher CRP levels
during collection of the first sputum study sample
(Table 2). Compared to surviving patients, the patients
who passed away in the ICU were significantly older,
had higher SAPS II and APACHE IV scores, and
showed higher levels of leukocytes, both in the category
lowest and highest measured during ICU admission.
The non-survivors had a significantly shorter length
of stay in the hospital (Table 2). Remarkably, statistical
analysis of the collected data showed that antimicrobial
activity in the first sputum sample is significantly
higher for patients who did not survive in the ICU
than for the ICU survivors. In a similar analysis,
where the average pneumococcal inhibition was com-
pared for sputum samples from patients who passed
away and patients who survived the ICU, no significant
difference was observed (Table 2).
As it is possible that the association between anti-
microbial activity in the first sputum sample and ICU
non-survival could be due to confounding by age or
disease severity (judged by the SAPS II or APACHE IV
scores), a multiple linear regression analysis was per-
formed, using the first sample inhibition halo diameter
as the dependent and ICU non-survival as the explana-
tory variable. Without the addition of age and/or dis-
ease severity as confounders, linear regression again
showed a significant correlation (p = 0.003), but includ-
ing only the SAPS II or APACHE IV score in the
regression model disproved the relationship
(p = 0.075 with the SAPS II, and p = 0.343 with the
APACHE IV score). These findings imply that disease
severity acted as a confounder, as both higher SAPS II
and APACHE IV scores are associated with antimicro-
bial activity in the first sputum sample, explaining the
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apparent association between non-survival and antimi-
crobial activity.
Discussion
The objective of this study was to assess the presence of
possible antimicrobial activity in the lungs of mechani-
cally ventilated patients, and to correlate this activity with
relevant patient characteristics. Despite the generally
acknowledged importance of antimicrobial activity in
protecting the human lung against infections, this has
not been systematically assessed to date. Accordingly, it
was not known how antimicrobial activity correlates with
patient characteristics, the composition of the lung
microbiome and, most importantly, patient outcome. To
address these questions with minimal patient discomfort,
we took advantage of the fact that the aspiration of spu-
tum is part of the routine care provided to mechanically
ventilated ICU patients. Normally, the collected sputa are
discarded, unless they are used for routine diagnostic
culturing to assess possible lung infection. Here we show
that sputa collected from different patients show a high
degree of variation in antimicrobial activity, which can
partially be attributed to antibiotic therapy. The sputum
microbiome, although potentially capable of producing
bactericidal agents (bacteriocins), seems to contribute in
a minor way, if any, to the antimicrobial activity of spu-
tum. Remarkably, despite the fact that antimicrobial
Table 2. Comparison of patient characteristics and antimicrobial activity against S. pneumoniae TIGR4 in sputum samples in relation









(n = 14) p-value
Female gender 4 (22.2) 17 (48.6) 0.063 13 (33.3) 8 (57.1) 0.118
Age (years) 58.5 [33.0–71.0] 56.0 [44.0–72.0] 0.749 55.0 [36.0–69.0] 65.0 [58.8–77.3] 0.048*
Hospital LOS (days) 21.9 [11.4–34.5] 16.7 [8.6–27.5] 0.523 19.8 [12.9–33.8] 11.0 [4.8–24.6] 0.023*
ICU LOS (days) 15.0 [7.9–22.7] 7.6 [4.9–15.1] 0.055 10.3 [6.0–20.1] 9.3 [4.8–15.5] 0.600
Admission diagnosis
Neurological 12 (66.7) 27 (77.1) 0.895 29 (74.4) 10 (71.4) 0.906
Respiratory 3 (16.7) 3 (8.6) 4 (10.3) 2 (14.3)
Medical 1 (5.6) 2 (5.7) 2 (5.1) 1 (7.1)
Cardiological 1 (5.6) 2 (5.7) 2 (5.1) 1 (7.1)
Gastroenterological 1 (5.6) 1 (2.9) 2 (5.1) 0 (0.0)
ICU outcome
Hospital transfer 13 (72.2) 24 (68.6) 0.586
Deceased 5 (27.8) 9 (25.7)
Nursing home 0 (0.0) 2 (5.7)
Mech. Vent. (hours) 280.0 [133.3–423.5] 115.0 [76.0–229.0] 0.010* 126.0 [78.0–297.0] 192.5 [110.5–329.0] 0.348
COPD 1 (5.6) 1 (2.9) 0.625 2 (5.1) 0 (0.0) 0.388
Pneumonia 13 (33.3) 5 (35.7) 0.872
SAPS II 51.1 ± 9.3 46.5 ± 14.0 0.163 (L 0.041) 44.6 ± 11.4 57.5 ± 11.6 0.001* (L 0.956)
APACHE IVa 81.4 ± 19.1 71.5 ± 24.5 0.145 (L 0.086) 67.9 ± 18.6 97.8 ± 21.3 <0.001* (L 0.587)
I.V. antibiotics 15 (83.3) 29 (82.9) 0.965 34 (87.2) 10 (71.4) 0.178
Cephalosporins (with or
without other antibiotics)
15 (83.3) 26 (74.3) 0.456 32 (82.1) 9 (64.3) 0.173
Other antibiotics (with or
without cephalosporins)
7 (38.9) 9 (25.7) 0.322 12 (30.8) 4 (28.6) 0.878
Only β-lactam antibiotics 9 (50.0) 25 (71.4) 0.123 27 (69.2) 7 (50.0) 0.198
Other antibiotics, with or
without β-lactam
antibiotics
6 (33.3) 4 (11.4) 0.054 7 (17.9) 3 (21.4) 0.775
No antibiotics 3 (16.7) 6 (17.1) 0.965 5 (12.8) 4 (28.6) 0.178
SDD topical antibiotics 15 (83.3) 27 (77.1) 0.599 32 (82.1) 10 (71.4) 0.401
Corticosteroids 5 (27.8) 11 (31.4) 0.784 12 (30.8) 4 (28.6) 0.878
Leukocytes
Sample§b 13.0 [11.2–17.1] 11.3 [9.3–15.0] 0.319 12.2 [8.7–15.2] 13.3 [10.5–20.1] 0.172
Lowest§§ 8.1 [6.3–9.7] 7.7 [5.6–9.6] 0.493 7.2 [5.7–9.3] 9.5 [7.9–12.1] 0.004*
Highest§§§ 20.1 [17.0–26.8] 18.0 [12.8–23.4] 0.229 17.9 [14.3–22.9] 21.4 [18.3–25.9] 0.030*
CRP
Sample§b 112.0 [52.0–264.8] 52.0 [20.5–114.0] 0.016* 68.5 [34.8–135.3] 52.0 [49.0–128.0] 0.801
Lowest§§ 12.4 [2.1–57.8] 4.4 [1.0–20.0] 0.260 5.5 [2.3–22.0] 6.4 [0.7–46.5] 0.635
Highest§§§ 166.0 [88.5–278.8] 119.0 [70.0–191.0] 0.086 133.0 [54.0–191.0] 162.0 [86.5–246.5] 0.323
First sample inhibition halo
(mm)
10.4 [0.0–20.3] 0.0 [0.0–19.1] 0.259 0.0 [0.0–15.6] 20.5 [0.0–28.6] 0.006*
Average inhibition halo
(mm)
12.0 [2.8–19.7] 4.7 [0.0–19.5] 0.304 4.8 [0.0–15.6] 16.3 [0.0–26.9] 0.083
The average S. pneumoniae TIGR4 growth inhibition is based on one to four sputum samples, depending on how many sputum samples were obtained from
each patient. §Leukocytes/CRP measured in blood at the time of first sputum sample collection, §§Lowest leukocytes/CRP measured in blood during ICU
admission, §§§Highest leukocytes/CRP measured in blood during ICU admission. Statistical analyses included the Pearson’s chi-squared test (n (%)), the
Mann-Whitney U test (median [IQR]) and the t-test (mean ± standard deviation).
* p-values ≤0.05 are considered significant. LLevene’s test significance. aAvailable for 50 patients; bavailable for 49 patients.
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activity is potentially protective, the level of antimicrobial
activity in the investigated sputa correlated inversely with
patient outcome in terms of ICU survival. However, the
latter correlation should be attributed to a confounding
effect of disease severity.
Substantial differences in growth inhibition by sputa
from different patients were observed for the three
indicator strains used in our study. Interestingly,
S. pneumoniae TIGR4 was more sensitive to the tested
sputa than S. anginosus 009–1 or S. aureus HG001. As
mentioned, S. anginosus 009–1 was isolated from one of
the investigated sputa and, accordingly, this isolate is
probably well-adapted for survival in sputum. In con-
trast, S. pneumoniae TIGR4 and S. aureus HG001 are
laboratory strains, whose ancestors were clinical isolates
from the blood of septic patients [28,29]. The difference
in ‘sputum susceptibility‘ between these two laboratory
strains is in line with the fact that S. aureus is, in
general, more robust than S. pneumoniae when cul-
tured in vitro. While we cannot exclude the possibility
that this difference in sputum susceptibility relates to
strain-specific features, it is tempting to hypothesize
that the observed difference is clinically relevant,
because the incidence of VAP caused by S. aureus is
up to 26-fold higher than that of VAP caused by
S. pneumoniae [17–19]. In this respect, it will be inter-
esting to investigate in future studies whether such
differences in sputum susceptibility are also evident
for Gram-negative bacteria implicated in VAP, such
as E. coli, H. influenzae, P. aeruginosa or
K. pneumoniae.
What is the nature of the observed antimicrobial
activity in sputa? More than 80% of the patients
included in this study received antibiotics intrave-
nously, cefotaxime in particular. Because cefotaxime
was detectable in 31 of 46 investigated sputa, it seems
likely that the antimicrobial activity of these sputa is
related to the presence of cefotaxime or cefotaxime-
derived desacetylcefotaxime [38]. Yet, 13 sputa with
cefotaxime concentrations higher than the MIC for
S. pneumoniae TIGR4 showed no or marginal growth
inhibition, suggesting that the cefotaxime present in
these sputa cannot exert its antimicrobial activity.
This might be due, for example, to sputum components
like mucin, as has previously been shown for colistin
[39]. Conversely, in six sputa from patients treated
intravenously with cefotaxime, this antibiotic was not
detectable or present below the MIC for S. pneumoniae
TIGR4, indicating that the antimicrobial activity in
these sputa may not relate (exclusively) to antibiotic
therapy. Thus, it seems that the latter sputa contained
antimicrobial compounds produced by the sputum
microbiome or the respective patient’s innate immune
system. However, it should be noted that mechanically
ventilated patients in our study group were subject to
SDD and that some of the applied non-absorbable
antimicrobial paste may have leaked into the sputum.
Also, some patients received antibiotics other than
cefotaxime (Figure 3(a)), and we cannot fully exclude
the possibility that some cefotaxime was degraded in
the time between the testing for antimicrobial activity
and the mass spectrometric assessment of cefotaxime
concentrations.
None of the 14 bacteria isolated from sputum dis-
played significant antimicrobial activity against the
three indicator strains in the strain-spotting assay. On
the other hand, 13 out of the 27 bacterial species from
the sputum microbiome, as identified by 16S rRNA
sequencing, do contain genes for known bacteriocins.
Thus, although not experimentally demonstrated,
a possible contribution of the sputum microbiome to
the detected antimicrobial activity of particular sputa is
conceivable. The latter view would be supported by the
fact that BAGEL4 revealed the presence of genes for
synthesis of the lantibiotic Gallidermin in S. aureus
HG001, which matches well with the observation that
S. aureus HG001 inhibited the growth of ten bacterial
sputum isolates. Even so, there was no correlation
detectable between the sputum microbiome, the poten-
tial of species identified in the sputum microbiome to
produce bacteriocins, and the actual antimicrobial
activity against S. pneumoniae TIGR4 as measured in
the different sputa. In particular, this is evident for
S. thermophilus, a bacterial species harboring many
bacteriocin genes that was almost evenly detectable in
sputa with high or low antimicrobial activity.
Intriguingly, several of the bacteria identified by 16S
rRNA sequencing are notorious pathogens, such as
K. pneumoniae, E. coli, S. pneumoniae, H. influenzae
and S. agalactiae. It is remarkable that these pathogens
were not always detected by routine culturing. This
suggests that their growth may have been suppressed
by antimicrobial therapy or other microbial species
present in the sample, or that they were simply not
recognized in a mixed culture. Further, it is noteworthy
that the 16S rRNA analysis did not detect S. aureus in
patients with pneumonia, despite the fact that S. aureus
is one of the most isolated species from patients with
VAP [17–19]. The latter may relate to the relatively
small sample size in our study.
Lastly, patients in our study cohort, who did not survive
hospitalization in the ICU, were significantly older, dis-
played higher disease severity scores (SAPS II, APACHE
IV) and had a shorter length of stay in the hospital com-
pared to patients who did survive in the ICU. While the
latter associations can be expected, the present observation
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that antimicrobial activity against S. pneumoniae TIGR4 in
sputa appeared to be inversely associated to ICU survival
was unexpected. However, this apparent association is
confounded by the disease severity, as inferred from the
fact that higher SAPS II and APACHE IV scores were
associated with antimicrobial activity in the first sputum
sample. Possibly this relates to an impaired barrier function
of the lung epithelium due to the patient’s frailty, which
could allow more influx of antibiotics into the alveoli.
Conceivably, these patients may also have displayed higher
inflammatory responses at the time of sputum sampling,
leading to higher levels of bactericidal compounds (e.g.
defensins and cationic antimicrobial peptides) in the
respective sputa. Leukocyte levels in blood were indeed
higher for non-survivors, both in the category lowest and
highest measured during ICU admission.
Interestingly, it was recently proposed that HAP may
relate to a dysbiosis of the lung microbiome, where
low-abundant and highly diverse microorganisms
would be rapidly replaced by a relatively high load of
particular respiratory pathogens, a process which could
be exacerbated by the administration of antibiotics [11].
However, we do not believe that this scenario is applic-
able to patients included in our present study, because
we did not observe an association between the admin-
istration of antibiotics and the risk of pneumonia.
In conclusion, the combined observations presented
in this study reveal that the sputa of mechanically
ventilated ICU patients contain variable levels of anti-
microbial compounds, including antibiotics such as
cefotaxime. The sputa display differential inhibitory
activities toward different pathogens as evidenced for
S. pneumoniae, S. anginosus and S. aureus.
Nevertheless, the level of sputum antimicrobial activity
correlated inversely with patient´s survival in the ICU,
most likely because disease severity outweighed the
potentially beneficial antimicrobial activities.
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